BioSpace News Archive

MaxCyte, Inc. today announced the signing of a strategic platform license (SPL).

Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in January.

Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc., announced the publication of the first framework paper for the clinical adoption and implementation of the optical genome mapping workflow for hematological malignancy applications, a process utilized by Bionano Laboratories in the development of its laboratory developed test, marketed as OGM-Dx™ HemeOne.

Keros Therapeutics, Inc. today announced that it plans to develop KER-065, a novel ligand trap designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A, for the treatment of obesity.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D. , founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that it is growing its distribution network by entering into an agreement with Walgreen Co. to distribute YCANTH™ through its specialty pharmacy.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C (ON) state.

NuView Life Sciences, Inc. announced the appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to its board of directors.

Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

QurAlis Corporation announced the opening of its European Union headquarters in Leiden, The Netherlands.